-transparent.png){kind=logo}
Angiotensin II was shown to activate S6-kinase in cultured vascular smooth muscle cells (VSMC) in a dose- (10(-9)-10(-6) M) and time-dependent manner. Pretreatment of quiescent cells with 12-O-Tetradecanoylphorbol-13-acetate had no effect on the activation levels of the kinase at the hormone levels used. However, stimulation of S6-kinase activity by angiotensin II was markedly inhibited by the inclusion of amiloride hydrochloride in serum-free medium during activation procedures. Angiotensin was not mitogenic for VSMC at even the highest doses used (10(-6) M). These findings support the notion that raised intracellular pH results in the activation of protein synthesis in quiescent cells.
T Scott-Burden, and
T J Resink, and
U Baur, and
M Bürgin, and
F R Bühler
May 2004,
Acta pharmacologica Sinica,
T Scott-Burden, and
T J Resink, and
U Baur, and
M Bürgin, and
F R Bühler
February 1995,
Atherosclerosis,
T Scott-Burden, and
T J Resink, and
U Baur, and
M Bürgin, and
F R Bühler
March 1995,
The Journal of biological chemistry,
T Scott-Burden, and
T J Resink, and
U Baur, and
M Bürgin, and
F R Bühler
February 1982,
The Journal of cell biology,
T Scott-Burden, and
T J Resink, and
U Baur, and
M Bürgin, and
F R Bühler
September 1992,
FEBS letters,
T Scott-Burden, and
T J Resink, and
U Baur, and
M Bürgin, and
F R Bühler
April 1989,
Hypertension (Dallas, Tex. : 1979),
T Scott-Burden, and
T J Resink, and
U Baur, and
M Bürgin, and
F R Bühler
January 1991,
Journal of hypertension,
T Scott-Burden, and
T J Resink, and
U Baur, and
M Bürgin, and
F R Bühler
May 2008,
Arteriosclerosis, thrombosis, and vascular biology,
T Scott-Burden, and
T J Resink, and
U Baur, and
M Bürgin, and
F R Bühler
January 2000,
Hypertension (Dallas, Tex. : 1979),
T Scott-Burden, and
T J Resink, and
U Baur, and
M Bürgin, and
F R Bühler
August 1996,
The American journal of physiology,
